Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study.
Objective. This open-label study examined the safety and efficacy of ziprasidone intramuscular with geriatric patients experiencing psychosis or agitation.Design. During an inpatient stay, consenting subjects who became acutely psychotic or agitated received ziprasidone intramuscular 10mg q 6 to 8 hours, up to a maximum dose of 20mg/24 hours. A within-group repeated measures design was employed to study whether the use of ziprasidone over the 24-hour observation period contributed to decreased agitation or to extrapyramidal side effects. The data were analyzed using an Analysis of Variance with trend analysis.Setting. The study was conducted on the geriatric psychiatry inpatient unit at the University of Toledo Medical Center, Toledo, Ohio.Participants. Fourteen patients, six men and eight women with mean age 77+/-8 years, participated in this study. Each patient had a diagnosis of dementia, co-occurring with one of the following: delirium, major depressive disorder with psychotic features, schizophrenia, bipolar disorder, or schizoaffective disorder.Measurements. The Brief Psychiatric Rating Scale, Delirium Rating Scale, and the Behavioral Activity Rating Scale were obtained at baseline and at 0.5, 2, and 24 hours after the first dose of ziprasidone intramuscular.Results. Overall, physiologic measures that would indicate undesirable side effects, including QTc intervals, remained unchanged pre- and post-study. However, there were significant improvements in scores on a variety of measures assessing agitation or psychosis.Conclusion. This study suggests that ziprasidone intramuscular may be a safe and effective short-term treatment for agitated or psychotic geriatric patients, and, therefore, additional studies should be conducted to confirm these findings.
Rais
Alina R
AR
Dr. Alina Rais is Associate Professor, Director Psychogeriatric Program of the University of Toledo Medical Center (UTMC), Toledo, Ohio.
Williams
Kristi
K
Rais
Theodor
T
Singh
Tanvir
T
Tamburrino
Marijo
M
Psychiatry Res. 1988 Jan;23(1):89-97
3363018
J Clin Psychopharmacol. 1998 Aug;18(4):296-304
9690695
J Clin Psychiatry. 2000 Dec;61(12):933-41
11206599
CNS Spectr. 2005 Sep;10(9):1-15
16247923
Int Clin Psychopharmacol. 2001 Jan;16 Suppl 1:S15-9
11252523
J Am Geriatr Soc. 1993 Jan;41(1):50-2
8418123
Am J Geriatr Pharmacother. 2005 Dec;3(4):240-5
16503319
Br J Psychiatry. 1989 May;154:672-6
2574607
Psychosomatics. 2002 Jan-Feb;43(1):61-2
11927760
Int J Psychiatry Med. 2005;35(1):91-8
15977947
J Psychiatr Res. 2002 Mar-Apr;36(2):87-95
11777497
J Psychiatr Pract. 2002 Mar;8(2):81-97
15985861
CNS Drugs. 2002;16(4):219-28
11945106
J Am Med Dir Assoc. 2009 Jan;10(1):21-7
19111849
Psychopharmacology (Berl). 2001 May;155(2):128-34
11401000
Psychopharmacology (Berl). 1998 Nov;140(2):173-84
9860108
Clin Neuropharmacol. 2005 May-Jun;28(3):111-4
15965308
Psychiatr Q. 2002 Winter;73(4):297-311
12418358
CNS Drugs. 2002;16(1):23-45
11772117
Eur Psychiatry. 2006 Dec;21(8):578-9
16139485
Dement Geriatr Cogn Disord. 2006;22(5-6):445-8
16983187
J Clin Psychiatry. 2005 Jul;66(7):928-9
16013910
Hum Psychopharmacol. 2005 Apr;20(3):203-5
15799011
Am J Geriatr Psychiatry. 2006 Jul;14(7):629-33
16816018